Recanalization of chronically occluded aortocoronary saphenous vein bypass grafts by extended infusion of urokinase: Initial results and short-term clinical follow-up  by Hartmann, Joseph R. et al.
JACC Vol. 18, No. 6 
November 15, 1991:1517-23 
REPORTS ON THERAPY 
1517 
Recanalization of Chronically Occluded Aortocoronary Saphenous 
Vein Bypass Grafts by Extended Infusion of Urokinase: Initial Results 
And Short-Term Clinical Follow-Up 
JOSEPH R. HARTMANN, MD, FACC, LOUIS S. McKEEVER, MD, FACC, 
NICHOLAS J. STAMATO, MD, FACC, VINCENT J. BUFALINO, MD, FACC, 
JOSEPH C. MAREK, MD, FACC, ALAN S. BROWN, MD, FACC, MARK J. GOODWIN, MD, FACC, 
JOHN M. CAHILL, MD, FACC, ELAINE L. ENGER, MS 
Downers Grove and Lombard, Illinois 
Chronic occlusion of saphenous vein aortocoronary bypass grafts 
is a common problem. Although percutaneous transluminal an-
gioplasty of a saphenous vein with a stenotic lesion is feasible, 
angioplasty alone of a totally occluded vein graft yields uniformly 
poor results. Patients with such occlusion are often subjected to 
repeat aortocoronary bypass surgery. Experience with a new 
technique that allows angioplasty to be performed in a totally 
occluded saphenous vein bypass graft is reported. This technique 
utilizes infusion of prolonged low dose urokinase directly into the 
proximal portion of the occluded graft. 
Forty-six consecutive patients with 47 totally occluded grafts 
were studied. Patients had undergone end to side saphenous vein 
bypass grafting 1 to 13 (mean 7) years previously. All patients 
presented with new or worsening angina pectoris with ST • T 
changes or non-Q wave acute myocardial infarction and all had a 
Saphenous vein graft occlusion is the predominant cause of 
recurrent ischemia in patients who have undergone coronary 
bypass surgery (1). Each year, > 14,000 repeat aortocoro-
nary bypass procedures are performed in the United States 
(2,3). Vein graft occlusion is prevalent during the 1st year 
after initial surgery. By 1 month after operation, up to 18% of 
vein grafts are occluded (4). At the end of the 1st postoper-
ative year, the incidence of closure escalates to between 16% 
and 30% (1,5,6). Closure rates >50% have been reported by 
11 years after bypass surgery (7). 
Thrombosis due to disruption of endothelial tissue and 
platelet activation during surgical manipulation appears to 
play a major role in early vein graft occlusion (4). The 
pathogenesis of late occlusion appears to be more complex. 
As a result of chronic injury, a hyperplastic proliferative 
response occurs, combined with a tendency toward throm-
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totally occluded saphenous vein bypass graft. The new technique 
entailed the positioning of an angiographic catheter into the stub 
of the occluded graft and the advancement of an infusion wire into 
the graft. Patients were returned to the coronary care unit, where 
urokinase was delivered at a dose of 100,000 to 250,000 U/h. The 
total dose of urokinase ranged from 0.7 to 9.8 million U over 7.5 
to 77 h (mean 31). After therapy, recanalization was seen in 37 
(79%) of the 47 grafts. 
In 20 successfully treated patients, angiography was performed 
1 to 24 (mean 11) months after treatment; 13 ( 65%) of these grafts 
were patent. It is concluded that direct, extended, low dose 
infusion of urokinase in a totally occluded saphenous vein bypass 
graft offers a promising alternative to repeat bypass surgery. 
(JAm Coli Cardiol1991;18:1517-23) 
bosis. Thus, a late graft occlusion is thought to result from an 
atherosclerotic-like lesion with or without associated throm-
bus. Although patients who receive antiplatelet therapy at 
the time of coronary artery bypass grafting and on a long-
term basis thereafter have a reduced rate of thrombotic 
occlusion, their risk still ranges between 9% and 20% by the 
end of the 1st year (5,8). 
Recurrent angina after aortocoronary bypass grafting 
may require repeat surgery. However, reoperation is asso-
ciated with up to twice the mortality rate of the initial 
procedure and is less effective at controlling angina (9, 10). 
Balloon angioplasty often fails to recanalize a totally oc-
cluded vein graft and exposes the patient to the risk of distal 
embolization ( 11). In addition, reocclusion of a graft opened 
by balloon angioplasty has been reported (12) to occur in 
approximately 33% of patients whose procedure is per-
formed within 3 years of graft placement and in 66% of those 
who undergo angioplasty > 3 years after coronary artery 
bypass grafting (12). 
In 1988, we reported (13) a new technique for dissolving 
thrombus in a chronically occluded aortocoronary saphen-
ous vein bypass graft; previous studies (14-16) had been 
limited to short-term infusion ( <2 h) of thrombolytic agents 
0735-1097/91/$3.50 
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in acutely occluded grafts. We treated 12 patients whose 
graft had been totally occluded for 2 to 8 weeks with 
extended infusion of low dose urokinase. Graft patency was 
demonstrated in 11 of 12 of these patients after treatment. 
In this report, we describe the treatment outcome in 46 
consecutive patients (including the original 12 patients) who 
had one or more completely occluded saphenous vein grafts 
who received extended urokinase infusion between January 
1987 and July 1990. We also report angiographic follow-up 
findings in 20 successfully treated patients. 
Methods 
Study patients. Between January 1987 and July 1990, 46 
consecutive patients underwent attempted recanalization of 
a chronically occluded aortocoronary saphenous vein by-
pass graft using this procedure. One patient had two oc-
cluded grafts treated. Forty patients were male (87%) and six 
were female (13%); their age ranged from 48 to 83 years 
(mean 60). Patients had undergone coronary bypass surgery 
between 1 and 13 (mean 7) years previously. All patients 
presented with signs and symptoms of ischemia; 5 (11%) 
with exertional angina and 41 (89%) with accelerating angina 
at rest. All patients developed ST segment and T wave 
abnormalities associated with chest pain or during exercise. 
Although the duration of potential graft occlusion was dif-
ficult to determine by history alone, it was estimated to range 
from 0.2 to 28 weeks. Patients with an acute Q wave 
myocardial infarction were excluded. However, the proce-
dure was attempted in eight patients who presented with a 
non-Q wave myocardial infarction. Twenty-eight patients 
( 61%) had a history of myocardial infarction before treat-
ment and 20 (43%) demonstrated myocardial infarction in the 
zone of the treated graft. All patients gave written informed 
consent. 
The sites of the 47 occluded grafts were: left anterior 
descending artery, 16 cases (34%); right coronary artery, 14 
cases (30%); obtuse marginal artery, 10 cases (21%); left 
circumflex artery, 4 cases (9%); and diagonal artery, 3 cases 
(6%). The native coronary vessel to the zone of the graft was 
occluded in 41 cases (87%). In 10 cases, angioplasty of 
vessels other than the target native vessel or graft was 
performed during the same hospitalization. 
Procedure. A 7F angiographic catheter was passed into 
the orifice of the occluded saphenous vein bypass graft using 
the Judkins technique. A 0.014-Hi-torque floppy guide wire 
was inserted into a 0.038- (145-cm) straight end-hole SOS 
infusion wire after the stylet was removed. The SOS guide 
wire assembly was advanced through a Toughy-Borst adap-
tor to the end of the angiographic catheter. The guide wire 
was then cautiously advanced as far as possible into the 
occluded graft. A steering handle attached to the guide wire 
facilitated manipulation of its preformed tip. In the event 
that the Hi-torque floppy guide wire could not be advanced, 
an intermediate or standard guide wire was substituted. Only 
minimal force was applied when passing the guide wire to 
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reduce the risk of perforation. Once the guide wire was 
positioned, the SOS wire was passed over the guide wire to 
a position several centimeters into the graft and the guide 
wire was then removed. The Toughy-Borst adaptor was 
tightened to secure the SOS wire position and an infusion 
adaptor was attached. 
A urokinase (Abbokinase, Abbott Laboratories) infusion 
was initiated both proximally through the angiographic cath-
eter and distally through the SOS wire at a rate of 50,000 U/h 
(total 100,000 U/h) (Fig. 1). The sheath and angiographic 
catheter were sutured to the skin and covered with a sterile 
dressing. The patient was brought to the critical care unit for 
continued coaxial urokinase infusion (Fig. 2). 
Heparin was administered intravenously throughout the 
procedure and the dose adjusted to maintain a partial throm-
boplastin time of 70 to 150 s. Prophylactic antibiotic therapy 
was instituted in patients requiring frequent catheter manip-
ulation or a longer duration of infusion. Fibrinogen, hemo-
globin and cardiac enzyme levels were monitored fre-
quently. Angiographic visualization was performed one to 
two times daily to determine the degree of thrombus disso-
lution. Provided there was no contraindication, the uroki-
nase dose was increased to a total dose of 250,000 U/h if 
thrombolysis was unsatisfactory at the time of revisualiza-
tion. In addition, the SOS infusion wire was advanced over 
a guide wire to the most distal point of occlusion. The 
urokinase infusion was typically discontinued when the graft 
appeared patent or when no progress in thrombolysis was 
evident after a minimum of 24 h. When flow was noted in the 
distal native coronary artery and a lesion was visualized, the 
graft was dilated by balloon angioplasty. In the event of 
residual thrombus after angioplasty, the urokinase infusion 
was continued for 4 to 24 h. 
Successfully treated patients were discharged on therapy 
with warlarin and aspirin unless these agents were contra-
indicated. Medical therapy with nitrates, a calcium channel 
antagonist or a beta-adrenergic blocking agent was pre-
scribed as necessary. 
Efficacy. Initial therapy was judged to be successful 
when the target vein graft demonstrated patency, defined as 
Thrombolysis in Myocardial Infarction (TIMI) grade II or III 
flow after thrombolytic infusion and balloon angioplasty. 
Therapy was judged a failure when the graft remained 
occluded defined as TIMI grade 0 or I flow after therapy ( 17). 
Complications. A prospective compilation of cerebrovas-
cular accidents, transient ischemic attacks, myocardial in-
farction, femoral artery occlusion or hematoma, systemic or 
local infections and the need for blood transfusion was 
performed during the hospital stay in which the procedure 
was conducted. 
Clinical and angiographic follow-up. All successfully 
treated patients were followed up for the development of 
recurrent angina, myocardial infarction, repeat coronary 
artery bypass surgery and death. The follow-up period 
ranged from 6 to 48 months (mean 27.2). Twenty patients 
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Figure 1. An SOS wire positioned several 
centimeters into the occluded graft. Coax-
ial urokinase infusion was given through 
the angiographic catheter (proximal) and 
SOS wire (distal). 
underwent follow-up angiography; 14 because of recurrent 
symptoms and 6 electively while free of symptoms. 
Results 
Initial therapy. Successful recanalization was achieved 
in 37 (79%) of 47 occluded saphenous vein bypass grafts. 
Adjunctive balloon angioplasty of a residual lesion was 
performed in 35 (95%) of these 37 cases; 7 patients also had 
angioplasty of other vessels performed after successful 
urokinase therapy. In 10 cases (21%), graft patency was not 
achieved; clinical details of the treatment failures appear in 
Table 1. Difficulty in positioning the angiographic catheter or 
SOS wire, or both, was experienced in five of these unsuc-
cessful cases. In two patients, the procedure was terminated 
prematurely as a consequence of discomfort associated with 
confinement of movement despite evidence of lysis in the 
proximal portion of the target graft. The procedure was 
discontinued in two patients by the investigator; in one 
because of a history of upper gastrointestinal bleeding and in 
the other because of a procedure-related femoral hematoma. 
At final angiography, the TIM! flow grades were as 
follows: grade III, 29 cases (62%); grade II, 8 cases (17%); 
grade I, 3 cases (6%); and grade 0, 7 cases (15%). The 
duration of urokinase infusion ranged from 7.5 to 77 h (mean 
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31). Total urokinase dose ranged from 0.72 to 9.79 million U. 
The duration of previous graft occlusion determined by 
history was 0.2 to 18 weeks (mean 2.4) in successfully 
treated patients and 0.2 to 28 weeks (mean 7.4) in those in 
whom the procedure failed to open the graft. 
Complications. A complication related to the procedure 
developed in 15 patients. Six patients (13%) developed chest 
pain and ST segment elevation suggestive of infarction 
during urokinase infusion. In the first patient, the urokinase 
infusion was discontinued and Q wave infarction developed. 
In the subsequent five patients, anterograde flow to the 
native coronary artery through the graft with significant 
residual thrombus was evident. Therefore, the urokinase 
dose was increased to a total of 200,000 to 250,000 U/h. In 
four of these five patients, chest pain subsided and ST 
segment elevation resolved without evidence of Q wave 
infarction. However, the fifth patient experienced local 
bleeding and hypotension requiring premature termination of 
therapy and later completed a Q wave infarction. 
Ten patients (22%) developed a significant hematoma. 
One patient (2%) experienced a decrease in hemoglobin to 
9.8 g/dl that necessitated a single unit blood transfusion and 
premature discontinuation of thrombolytic therapy. Four 
additional patients (9%) demonstrated a decrease in hemo-
globin of approximately 2 g/dl for which transfusion was not 
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deemed necessary. Fibrinogen levels were measured in all 
patients during therapy. In one patient, the nadir fibrinogen 
level was < 100 mg/dl; in seven patients, a level <200 mg/dl 
was demonstrated. No patient exhibited transient or perma-
nent neurologic symptoms or findings. 
Clinical follow-up. All successfully treated patients were 
followed up clinically for symptoms of angina pectoris, 
myocardial infarction, abnormal exercise electrocardio-
graphic findings and the need for further intervention. The 
mean follow-up interval was 27.2 months (range 6 to 48). 
During the follow-up period, 14 patients experienced angina 
pectoris, 2 developed congestive heart failure and 4 under-
went repeat aortocoronary bypass surgery. There were four 
deaths during the follow-up period (two sudden, one due to 
congestive heart failure and one in which circumstances are 
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Figure 2. Illustration of limb demon-
strating the procedural set-up. 
unknown). Twenty-two patients (61%) remained free of 
symptoms during the follow-up period. 
Angiographic follow-up. Twenty successfully treated pa-
tients underwent repeat angiography during the 27-month 
follow-up period. Fourteen patients returned with angina 
pectoris; six remained asymptomatic and underwent elective 
angiography. The clinical characteristics of these 
20 patients are presented in Table 2. The grafts in 13 pa-
tients (65%) were patent (Fig. 3, A to E), but 2 of the 13 
required angioplasty for recurrent graft stenosis. Ten of 
these patients had been maintained on warfarin therapy 
after their recanalization procedure. The grafts in seven 
patients (35%) were occluded; six of these patients had been 
treated with long-term warfarin therapy. Of the seven pa-
tients with an occluded bypass graft, four underwent repeat 
JACC Vol. 18, No. 6 
November 15, 1991:1517-23 
HARTMANN ET AL. 1521 
RECANALIZATION OF OCCLUDED BYPASS GRAFTS 
Table 1. Clinical Characteristics of lO Patients Experiencing a Urokinase Treatment Failure 
Urokinase 
Pt Age (yr)/ Duration of Total Dose 
No. Gender Graft Site Infusion (h) (U) Comments 
62/M OM 72 2,700,000 No refiow phenomenon 
2 62/F LAD 21 1,260,000 Difficulty positioning catheter; discontinued by patient 
3 62/F RCA 18 1,800,000 Discontinued by patient 
4 52/M Diag 17.5 1,300,000 Difficulty positioning catheter 
5 61/M LAD 17 850,000 Difficulty positioning catheter 
6 83/F Diag 42 4,200,000 No reftow phenomenon 
7 52/M OM 15.5 1,500,000 Difficulty positioning catheter 
8 62/M OM 22.75 2,275,000 Difficulty positioning catheter 
9 56/F OM 27.5 4,500,000 Discontinued by investigator because of a history of bleeding 
10 53/M RCA 33.75 4,570,000 Discontinued by investigator because of an adverse event 
(see text) 
Diag = diagonal branch; F = female; LAD= left anterior descending coronary artery; M = male; OM = obtuse marginal branch; Pt = patient; RCA = right 
coronary artery. 
bypass surgery, two were successfully treated with repeat 
extended urokinase infusion and one patient was treated 
medically. 
Discussion 
Initial therapy. The technique of prolonged urokinase 
infusion into a saphenous vein bypass graft was first at-
tempted with use of a protocol similar to that used for 
chronic peripheral arterial thrombosis (13). Our present 
experience yielded a 79% success rate and we have identified 
several factors that appear to predict success. l) Recently 
occluded bypass grafts apparently respond to urokinase 
therapy more frequently than do grafts known or thought to 
be occluded for a longer time. Thus, although the precise 
interval of graft occlusion is difficult to determine by history 
alone, the duration of graft occlusion ranged from 0.2 to 18 
weeks (mean 2.4) in the patients with successful recanaliza-
tion compared with 0.2 to 28 weeks (mean 7.4) in those in 
whom the procedure failed. 2) To be amenable to this 
Table 2. Long-Term Follow-Up of 20 Patients After Successful Extended Urokinase Infusion 
Years After Follow-Up After Urokinase 
CABG* to Total 
Pt Age (yr)/ Initial Site of Urokinase Urokinase Duration Graft 
No. Gender Occlusion Infusion Dose (U) (mo) Reason Status* 
I 48/M LAD 4 4,000,000 6 Elective Patent 
2 63/M RCA 8 2,400,000 3 Symptoms Patent 
3 54/M LCx 8 4,649,000 24 Symptoms Occluded 
4 67/M OM 10 3,725,000 23 Symptoms Patent 
5 65/M RCA I 4,400,000 Symptoms Patent 
6 56/M LAD 11 1,600,000 22 Symptoms Occluded 
7 69/M OM 2,400,000 5 Symptoms Occluded 
8 64/M OM 10 3,900,000 5 Elective Patent 
9 66/M RCA 4 6,950,000 22 Symptoms Occluded 
10 69/M OM 8 1,600,000 24 Elective Patent 
11 55/M RCA 12 870,000 5 Symptoms Patent 
12 73/M LAD 5 825,000 2 Symptoms Patent 
13 61/M LCx 4 4,750,000 3 Symptoms Occluded 
14 63/M LAD 6 9,690,000 I Symptoms Patent 
15 67/M RCA 3 5,925,000 8 Elective Patent 
16 65/M OM 7 1,670,000 12 Symptoms Patent 
17 62/M RCA 9 7,560,000 9 Symptoms Occluded 
18 65/M RCA 3 2,600,000 9 Elective Occluded 
19 49/M RCA 4 4,875,000 7 Elective Patent 
20 57/M Diag 9 720,000 13 Symptoms Patent 
*Patients 3, 6, 7 and 17 underwent repeat coronary artery bypass grafting. Patient 18 was medically managed. Patients 9 and 13 underwent repeat urokinase 
infusion followed by successful angioplasty. CABG = coronary artery bypass grafting; LCx = left circumflex coronary artery; other abbreviations as in 
Table I. 
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Figure 3. Sequential angiograms from the same patient. 
A, Total occlusion of circumflex artery graft. B, The 12-h 
revisualization of distal circumflex artery graft showing 
partial recanalization. C, Preangioplasty site of stenosis in 
the graft (arrow) with a totally recanalized distal vessel. 
D, Circumflex artery graft at the completion of angio-
plasty (arrow). E, Circumflex artery graft at I year of 
follow-up. 
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procedure, the saphenous vein graft must have a stub that 
facilitates reliable positioning of both the catheter and the 
infusion wire. 3) Although difficult to quantify, the presence 
of significant viable myocardium in the distribution of the 
vein graft appears to allow for greater success. 4) Patient 
acceptance of the prolonged time (up to 77 h) required for 
successful lysis is necessary, Because patient discomfort 
secondary to restricted body movement may be significant, 
adequate analgesia and sedation are mandatory. 
The relative lack of acute complications during the pro-
cedure is of significance. No central nervous system events 
or symptoms were noted in any patient. Although all patients 
were receiving optimal maintenance anticoagulant therapy 
with heparin during the thrombolytic period, bleeding com-
plications were minimal. Only one patient (2%) required 
blood transfusion. 
The problem of embolic myocardial infarction and myo-
cardial ischemia requires special attention. We previously 
reported (18) on three patients with this condition and have 
now observed it in a total of six patients (13%), In four of 
these patients, increasing the dose of urokinase resulted in 
the resolution of the signs of ischemia and little or no 
evidence of myocardial necrosis. Of the six patients, three 
presented with prior evidence of an infarct in the zone of the 
graft. Given the small number of patients exhibiting this 
phenomenon, further investigation is required to identify 
potential predisposing factors. 
Clinical and angiographic follow-up. Although the clinical 
follow-up period is limited to a mean of 27 months and 
the angiographic follow-up to 20 patients, the results are 
encouraging. The 65% confirmed patency rate and the 61% 
freedom from recurrent angina are exceptional given the 
significant symptoms in this group at baseline. In addition, 
two patients with reocclusion were successfully retreated 
with urokinase infusion. Although no clear trend toward 
improvement in long-term graft patency among patients 
maintained on warfarin therapy was demonstrated, we cur-
rently place all patients with a successfully recanalized graft 
on both warfarin and aspirin therapy before hospital dis-
charge. 
Conclusions. Although broader, more widespread expe-
rience needs to be gathered to define the risk of myocardial 
infarction, cerebrovascular accident and other complica-
tions, our initial results and follow-up data suggest that 
extended infusion of urokinase in occluded saphenous vein 
bypass grafts offers an excellent treatment option for se-
lected patients with resistant symptoms due to vein graft 
occlusion. In carefully selected patients, it is a safe and 
effective alternative to repeat aortocoronary bypass surgery. 
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